Across TCGA pan-cancer cohorts, IGHV3-23 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV3-23 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGHV3-23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-23 expression acts as an unfavorable survival marker.

STAD, COAD, and UCEC are the cancer types where IGHV3-23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.074	0.688	<.001	48	view →
COAD	OS	Median	All	0.100	0.670	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGHV3-23 tumor-vs-normal RNA expression · all IGHV3-23 data types